<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: AstraZeneca give double update on Monday including Brilinta outcome	</title>
	<atom:link href="https://ukinvestor.foxrobinson.com/astrazeneca-give-double-update-on-monday-and-update-on-two-drug-trials/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestor.foxrobinson.com/astrazeneca-give-double-update-on-monday-and-update-on-two-drug-trials/</link>
	<description></description>
	<lastBuildDate>Tue, 25 Feb 2020 11:09:29 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.6.2</generator>
	<item>
		<title>
		By: AstraZeneca sublicense Movantik to RedHill Biopharma - UK Investor Magazine		</title>
		<link>https://ukinvestor.foxrobinson.com/astrazeneca-give-double-update-on-monday-and-update-on-two-drug-trials/#comment-14468</link>

		<dc:creator><![CDATA[AstraZeneca sublicense Movantik to RedHill Biopharma - UK Investor Magazine]]></dc:creator>
		<pubDate>Tue, 25 Feb 2020 11:09:29 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestor.foxrobinson.com/?p=26435#comment-14468</guid>

					<description><![CDATA[[&#8230;] is indicated as a treatment for opioid-induced constipation &#8211; and Redhill are set to pay AstraZeneca $52.5 million upfront for the global rights &#8211; excluding Israel, Canada, and Europe. [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] is indicated as a treatment for opioid-induced constipation &#8211; and Redhill are set to pay AstraZeneca $52.5 million upfront for the global rights &#8211; excluding Israel, Canada, and Europe. [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
